sevoflurane has been researched along with Pulmonary Arterial Hypertension in 1 studies
Sevoflurane: A non-explosive inhalation anesthetic used in the induction and maintenance of general anesthesia. It does not cause respiratory irritation and may also prevent PLATELET AGGREGATION.
sevoflurane : An ether compound having fluoromethyl and 1,1,1,3,3,3-hexafluoroisopropyl as the two alkyl groups.
Pulmonary Arterial Hypertension: A progressive rare pulmonary disease characterized by high blood pressure in the PULMONARY ARTERY.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim of this study was to explore the influences of sevoflurane inhalation therapy on circulation function and pulmonary fibrosis in rats with pulmonary arterial hypertension (PAH) and the nuclear factor-κB (NF-κB) signaling pathway." | 7.91 | Sevoflurane improves circulatory function and pulmonary fibrosis in rats with pulmonary arterial hypertension through inhibiting NF-κB signaling pathway. ( Bai, X; Li, JL; Li, SM; Xi, J; Zhao, X, 2019) |
| "The aim of this study was to explore the influences of sevoflurane inhalation therapy on circulation function and pulmonary fibrosis in rats with pulmonary arterial hypertension (PAH) and the nuclear factor-κB (NF-κB) signaling pathway." | 3.91 | Sevoflurane improves circulatory function and pulmonary fibrosis in rats with pulmonary arterial hypertension through inhibiting NF-κB signaling pathway. ( Bai, X; Li, JL; Li, SM; Xi, J; Zhao, X, 2019) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Zhao, X | 1 |
| Bai, X | 1 |
| Li, JL | 1 |
| Li, SM | 1 |
| Xi, J | 1 |
1 other study available for sevoflurane and Pulmonary Arterial Hypertension
| Article | Year |
|---|---|
Sevoflurane improves circulatory function and pulmonary fibrosis in rats with pulmonary arterial hypertension through inhibiting NF-κB signaling pathway.
Topics: Administration, Inhalation; Animals; Disease Models, Animal; Down-Regulation; Humans; I-kappa B Prot | 2019 |